Speech-Language Pathologists in Alexandria, KY Accepting Medicare

7 Speech-Language Pathologists found. Showing 1 - 7

Ann King, SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 8109 Alexandria Pike, Suite 4, Alexandria, KY 41001 Phone: 859-635-6500

Joni Lyn Hall, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 7495 Dornoch Ln, Alexandria, KY 41001 Phone: 270-999-1355

Kathleen Carrillo, M.S. CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 876 Yorkshire Dr, Alexandria, KY 41001 Phone: 812-622-0448

Susan Buscher Speech-Language Pathologist Medicare: Medicare Enrolled Practice Location: 7341 E Alexandria Pike, Alexandria, KY 41001 Phone: 859-694-4450

Mrs. Stephanie Lynn Anthrop, SPEECH-LANG PATH Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1078 Summerlake Dr., Alexandria, KY 41001 Phone: 859-582-4076

Amberly Nicole Stanton, MA CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 11903 Skyview Dr, Alexandria, KY 41001 Phone: 859-802-7001

Mrs. Amy Purvis, SPEECH LANG PATH Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6 S Longwood Ct, Alexandria, KY 41001 Phone: 859-358-7753

News Archive

NSAID Celebrex may help prevent non-melanoma skin cancer development: Research

New research shows the NSAID Celebrex may help prevent some non-melanoma skin cancers from developing in patients who have pre-cancerous actinic keratoses lesions and are at high risk for having the disease.

Link between insomnia and obesity

A possible link between lack of sleep (insomnia) and obesity has been traced to hypocretin/orexin cells in the hypothalamus region of the brain that are easily excited and sensitive to stress, Yale School of Medicine researchers report in the April issue of Cell Metabolism.

XTL Biopharmaceuticals purchases 4,620,356 shares of Proteologics from Teva

XTL Biopharmaceuticals Ltd., a biopharmaceutical development company, announced on November 21st that it has acquired 4,620,356 shares, of Proteologics Ltd., from Teva Pharmaceutical Industries Ltd. in consideration for an amount of approximately NIS 6.5 million, which represents an amount of NIS 1.405 per Share (approximately 22% premium).

ZenBio to be commercial source for popular murine 3T3-L1 cell line

ZenBio announce that they will be a commercial source for the popular murine 3T3-L1 cell line, which has been fundamental in metabolic disease research for 30 years.

PCSK9 inhibitor can reduce need for apheresis treatment in patients with familial hypercholesterolemia

Patients who have heterozygous familial hypercholesterolemia (HeFH), a condition that causes abnormally raised low-density lipoprotein cholesterol (LDL-C) levels and premature cardiovascular disease, can significantly reduce or even eliminate their need for expensive and time-consuming apheresis treatments with the PCSK9 inhibitor alirocumab.

Read more Medical News

› Verified 3 days ago